Market Overview:
The global multiple myeloma drugs market is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of multiple myeloma, rising awareness about available treatment options, and technological advancements in the field of cancer treatment. Based on type, the global multiple myeloma drugs market is segmented into immunomodulatory drugs (IMiDs), proteasome inhibitors, chemotherapy, histone deacetylase inhibitor (HDAC inhibitor), and steroids (corticosteroids). Immunomodulatory drugs are further sub-segmented into thalidomide and lenalidomide. Proteasome inhibitors are further sub-segmented into bortezomib and carfilzomib. Chemotherapy is further sub-segmented into alkylating agents, antimetabolites, anthracyclines/taxanes,. HDAC inhibitors are further sub-segmented into vorinostat and panobinostat. Steroids are further sub-segmented into corticosteroids and nonsteroidal antiinflammatory drugs (NSAIDs). Based on application, the global multiple myeloma drugs market is segmentedinto menand women.
Product Definition:
Multiple myeloma (MM) is a cancer of plasma cells, which are white blood cells that help fight infection. MM often affects the bones, causing pain and fractures. The cause of MM is not known. However, it is thought that the disease may develop when abnormal plasma cells grow out of control and produce too much antibody protein.
Immunomodulatory drugs (IMiDs):
Immunomodulatory drugs (IMiDs) are a new class of medication that affects the immune system by modifying its activity. IMiDs have shown positive results in clinical trials for the treatment of multiple myeloma and other blood cancers. Immunomodulatory drugs can be divided into two classes, cytokines and non-cytokines based on their mechanism of action.
Proteasome inhibitors:
Proteasome inhibitors are a new type of drug for the treatment of multiple myeloma. They block the proteasome, an important protein breakdown machinery in cells. Blocking this process results in increased levels of proteins that promote cell death orapoptosis. These drugs may be used alone or along with other treatments such as immunomodulators and chemotherapy to enhance their effectivity against multiple myeloma cancer cells.
Application Insights:
Men application segment dominated the global market in terms of revenue share in 2017. Increasing awareness about MMD and rising number of diagnosed patients are factors contributing to the growth of this segment. In addition, increasing availability and affordability of healthcare services is expected to boost the usage rate for men suffering from MMD.
The women application segment is expected to witness lucrative growth over the forecast period due to increasing prevalence rates for multiple myeloma as well as other cancer types across developed countries such as U.S., Canada, Germany, France and UK along with developing countries such as China, India Africa etc. Moreover, there are various clinical trials ongoing for treating women with different drugs combinations which will further boost market penetration during the forecast period (see table below).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and high healthcare expenditure are some of the factors responsible for its large share. Moreover, increasing prevalence of multiple myeloma is also expected to drive growth over the forecast period. For instance, as per an annual survey conducted by Multiple Myeloma Research Foundation (MMRF), Inc., around 13000 people were diagnosed with multiple myeloma in North America alone in 2018; this number is expected to reach 17000 by 2020 if immediate steps are not taken.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure coupled with growing awareness about early diagnosis & treatment options for various diseases including multiple myeloma. Furthermore, availability of effective treatment methods at lower costs compared to developed regions will further propel regional growth during the estimated time frame (2018-2030).
Growth Factors:
- Increasing incidence of multiple myeloma
- Growing demand for novel and targeted therapies
- Rising awareness about multiple myeloma and its treatment options
- Availability of government funding for research on multiple myeloma drugs
- Technological advancements in the field of cancer therapy
Scope Of The Report
Report Attributes
Report Details
Report Title
Multiple Myeloma Drugs Market Research Report
By Type
Immunomodulatory drugs (IMiDs), Proteasome inhibitors, Chemotherapy, Histone deacetylase inhibitor (HDAC inhibitor), Steroids (corticosteroids)
By Application
Men, Women
By Companies
Amgen, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, Merck, AB Science, Teva, PharmaMar
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Multiple Myeloma Drugs Market Report Segments:
The global Multiple Myeloma Drugs market is segmented on the basis of:
Types
Immunomodulatory drugs (IMiDs), Proteasome inhibitors, Chemotherapy, Histone deacetylase inhibitor (HDAC inhibitor), Steroids (corticosteroids)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Men, Women
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Johnson & Johnson
- Celgene
- Takeda Pharmaceutical
- Novartis
- Daiichi Sankyo
- Merck
- AB Science
- Teva
- PharmaMar
Highlights of The Multiple Myeloma Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunomodulatory drugs (IMiDs)
- Proteasome inhibitors
- Chemotherapy
- Histone deacetylase inhibitor (HDAC inhibitor)
- Steroids (corticosteroids)
- By Application:
- Men
- Women
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Multiple Myeloma Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Multiple myeloma drugs are medications used to treat multiple myeloma. These drugs can help to slow the growth of the cancer and may also help to prevent it from spreading.
Some of the major players in the multiple myeloma drugs market are Amgen, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, Merck, AB Science, Teva, PharmaMar.
The multiple myeloma drugs market is expected to grow at a compound annual growth rate of 7.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Multiple Myeloma Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Multiple Myeloma Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Multiple Myeloma Drugs Market - Supply Chain
4.5. Global Multiple Myeloma Drugs Market Forecast
4.5.1. Multiple Myeloma Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Multiple Myeloma Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Multiple Myeloma Drugs Market Absolute $ Opportunity
5. Global Multiple Myeloma Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Multiple Myeloma Drugs Market Size and Volume Forecast by Type
5.3.1. Immunomodulatory drugs (IMiDs)
5.3.2. Proteasome inhibitors
5.3.3. Chemotherapy
5.3.4. Histone deacetylase inhibitor (HDAC inhibitor)
5.3.5. Steroids (corticosteroids)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Multiple Myeloma Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Multiple Myeloma Drugs Market Size and Volume Forecast by Application
6.3.1. Men
6.3.2. Women
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Multiple Myeloma Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Multiple Myeloma Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Multiple Myeloma Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Multiple Myeloma Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Multiple Myeloma Drugs Demand Share Forecast, 2019-2026
9. North America Multiple Myeloma Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Multiple Myeloma Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Multiple Myeloma Drugs Market Size and Volume Forecast by Application
9.4.1. Men
9.4.2. Women
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Multiple Myeloma Drugs Market Size and Volume Forecast by Type
9.7.1. Immunomodulatory drugs (IMiDs)
9.7.2. Proteasome inhibitors
9.7.3. Chemotherapy
9.7.4. Histone deacetylase inhibitor (HDAC inhibitor)
9.7.5. Steroids (corticosteroids)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Multiple Myeloma Drugs Demand Share Forecast, 2019-2026
10. Latin America Multiple Myeloma Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Multiple Myeloma Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Multiple Myeloma Drugs Market Size and Volume Forecast by Application
10.4.1. Men
10.4.2. Women
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Multiple Myeloma Drugs Market Size and Volume Forecast by Type
10.7.1. Immunomodulatory drugs (IMiDs)
10.7.2. Proteasome inhibitors
10.7.3. Chemotherapy
10.7.4. Histone deacetylase inhibitor (HDAC inhibitor)
10.7.5. Steroids (corticosteroids)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Multiple Myeloma Drugs Demand Share Forecast, 2019-2026
11. Europe Multiple Myeloma Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Multiple Myeloma Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Multiple Myeloma Drugs Market Size and Volume Forecast by Application
11.4.1. Men
11.4.2. Women
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Multiple Myeloma Drugs Market Size and Volume Forecast by Type
11.7.1. Immunomodulatory drugs (IMiDs)
11.7.2. Proteasome inhibitors
11.7.3. Chemotherapy
11.7.4. Histone deacetylase inhibitor (HDAC inhibitor)
11.7.5. Steroids (corticosteroids)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Multiple Myeloma Drugs Demand Share, 2019-2026
12. Asia Pacific Multiple Myeloma Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Multiple Myeloma Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Multiple Myeloma Drugs Market Size and Volume Forecast by Application
12.4.1. Men
12.4.2. Women
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Multiple Myeloma Drugs Market Size and Volume Forecast by Type
12.7.1. Immunomodulatory drugs (IMiDs)
12.7.2. Proteasome inhibitors
12.7.3. Chemotherapy
12.7.4. Histone deacetylase inhibitor (HDAC inhibitor)
12.7.5. Steroids (corticosteroids)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Multiple Myeloma Drugs Demand Share, 2019-2026
13. Middle East & Africa Multiple Myeloma Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Multiple Myeloma Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Multiple Myeloma Drugs Market Size and Volume Forecast by Application
13.4.1. Men
13.4.2. Women
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Multiple Myeloma Drugs Market Size and Volume Forecast by Type
13.7.1. Immunomodulatory drugs (IMiDs)
13.7.2. Proteasome inhibitors
13.7.3. Chemotherapy
13.7.4. Histone deacetylase inhibitor (HDAC inhibitor)
13.7.5. Steroids (corticosteroids)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Multiple Myeloma Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Multiple Myeloma Drugs Market: Market Share Analysis
14.2. Multiple Myeloma Drugs Distributors and Customers
14.3. Multiple Myeloma Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Johnson & Johnson
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celgene
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Takeda Pharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Daiichi Sankyo
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AB Science
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Teva
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. PharmaMar
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
